The mRNA Melanoma Vaccine: What the INTerpath-001 Result Actually Says

What was announced

On August 19, 2026, Merck and Moderna said that a large trial of an mRNA cancer vaccine had worked.

The vaccine is called intismeran autogene, previously known as mRNA-4157 or V940. It was tested in people whose melanoma had been surgically removed but was likely to come back. Everyone in the trial received Keytruda, the standard immunotherapy after that kind of surgery. Half again as many also received the vaccine.

The group that got both went longer before the melanoma returned, and longer before it spread to distant parts of the body, than the group that got Keytruda alone.

That is the whole result. It has not yet been published in a medical journal, presented at a conference, or reviewed by the Food and Drug Administration. The companies say they will present the data at a medical meeting and talk to regulators about filing.

What a personalized mRNA cancer vaccine is

The word "vaccine" is doing something unusual here. This is not a shot to stop you getting cancer. It is given to people who already had cancer, to teach the immune system to hunt whatever might be left.

Cancer cells carry mutated proteins that healthy cells do not. The National Cancer Institute calls these neoantigens, and describes them as faulty alarms — flags that should tell the immune system a cell has gone wrong. Often the alarm is ignored.

Making the vaccine works roughly like this:

1. Surgeons remove the tumor.
2. The tumor's genetic code is read and compared with the person's healthy cells, to find the mutations unique to the cancer.
3. Software picks the mutations most likely to provoke an immune response. Intismeran encodes up to 34 of them.
4. Those instructions are written into mRNA — the same kind of molecule used in the Covid vaccines, carrying a different message.
5. The person is injected with it. Their own cells read the instructions, build the flagged proteins, and the immune system learns the pattern.

Every dose is manufactured for one person. Nobody else's would work.

The NCI has reported small trials of this approach in kidney and pancreatic cancer, where the most convincing evidence was not the survival numbers but the immune response itself. Mark Ball, an NCI researcher, described patients whose T cells still recognized their tumor's neoantigens years after treatment ended.

Trial at a glance

Field	Detail
Trial	INTerpath-001 (V940-001)
Registry number	NCT05933577
Phase	3, randomized, double-blind, international
Participants	1,137
Population	Completely resected stage IIB–IV melanoma, no prior systemic therapy
Allocation	2:1 — vaccine plus Keytruda, versus Keytruda alone
Vaccine dosing	1 mg every three weeks, up to 9 doses
Keytruda dosing	400 mg every six weeks, about one year
Main measures	Recurrence-free survival; distant metastasis-free survival
Status	Ongoing; interim analysis reported August 2026

Both amounts above are trial doses on a fixed schedule, given in a clinical trial rather than prescribed. What any individual receives is decided by their own care team.

Recurrence-free survival counts the time until the melanoma comes back anywhere, or the person dies. Distant metastasis-free survival counts the time until it appears somewhere far from where it started — the lungs, liver, brain — which is the event that changes the outlook most.

What the companies reported, and what they did not

Merck's announcement says the improvement in both measures was statistically significant and clinically meaningful, and that this is the first Phase 3 study to beat Keytruda alone in this setting. It says the safety profile matched what had been seen before, with no new safety signals.

It does not give the numbers. There is no hazard ratio in the release, no percentages, no median follow-up. Those are the figures that tell you how large the benefit is, and they are still to come.

An interim analysis also means the trial is not finished. Its primary completion date is listed as October 2029.

Stephen Hoge, Moderna's president, told STAT that the company had not expected this: "None of us believed it."

Why this is being talked about beyond melanoma

mRNA has had a difficult few years in the United States, caught up in arguments about Covid vaccines that have little to do with its use against cancer. Coverage of this result has focused as much on that as on the medicine.

Ryan Sullivan, a Mass General Brigham physician who has worked with Moderna, told STAT he hoped the result might "thaw some of the stigma around vaccines," while acknowledging one trial will not do that on its own.

For a reader trying to decide what to make of it, the political framing is a distraction. The question is whether the benefit holds up when the numbers are published.

What this does not mean for you today

• The vaccine is not available. It is not approved by the FDA and cannot be prescribed. The only route to it is a clinical trial.
• Approval is not certain. A company saying a trial met its endpoints is the beginning of the regulatory process. The FDA notes that even breakthrough therapy designation, which speeds up meetings and review, does not guarantee approval.
• It was tested in one specific situation. Stage IIB–IV melanoma, completely removed by surgery, no previous systemic treatment. It says nothing yet about melanoma that cannot be removed, or about other cancers, though trials in lung and other cancers are running.
• It is added to Keytruda, not a replacement for it. Both arms of the trial received Keytruda.
• Most melanoma is caught early and does well. SEER, the federal cancer surveillance program, puts five-year relative survival for melanoma of the skin at about 96.5 percent overall, and 77 percent of cases are found while still localized. This trial was about the higher-risk minority.

Signs worth a call, not a wait

Melanoma is one of the cancers where looking matters. A spot that has changed is the thing to act on.

• A mole that changes in size, shape, or color, or has an uneven border or more than one color.
• A new spot that looks different from your others.
• A sore that does not heal within a few weeks.
• Itching, bleeding, or crusting from a mole.
• A dark streak under a fingernail or toenail that you cannot explain.
• After melanoma surgery: a lump under the skin near the scar, a swollen lymph node, or persistent new symptoms such as headache, breathlessness, or unexplained weight loss. These go to the treating team.

Sources

• Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS in Completely Resected Stage IIB-IV Melanoma (August 19, 2026)
• STAT: Inside Moderna and Merck's cancer vaccine triumph (August 24, 2026)
• STAT: After a rough stretch, mRNA gets a boost — at least for now (August 31, 2026)
• NCI Cancer Currents: Personalized neoantigen vaccines for pancreatic and kidney cancer
• ClinicalTrials.gov API v2 record for NCT05933577
• FDA: Frequently Asked Questions — Breakthrough Therapies
• NCI SEER Cancer Stat Facts: Melanoma of the Skin

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.